RxDoctor Payments Data

Michael Rzasnicki, MD

Family Medicine · Cypress, TXNPI 1982699575

Payments from drug & device makers

$4,206in general payments, 2019–2025

Across 255 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Boehringer Ingelheim$460
  • Exact Sciences$360
  • AstraZeneca$296
  • Pfizer$284
  • Amgen$225
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,17199%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,206 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$342,402
Medicare patients
1,175
Services billed
5,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$142,899
EliquisApixaban91$84,242
XareltoRivaroxaban56$61,880
MounjaroTirzepatide45$53,898
FarxigaDapagliflozin Propanediol34$48,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$35,933
JanuviaSitagliptin Phosphate21$30,673
MyrbetriqMirabegron19$21,534
JardianceEmpagliflozin13$18,511
LinzessLinaclotide14$15,565
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,944
Atorvastatin Calcium537$5,423
Levothyroxine Sodium396$4,868
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$4,591
Tamsulosin Hcl213$4,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,049$142,89989 claims
PfizerEliquis$284$84,24291 claims
Johnson & JohnsonXarelto$44$61,88056 claims
Lilly USA, LLCMounjaro$25$53,89845 claims
AstraZenecaFarxiga$296$48,81134 claims
GSKTrelegy Ellipta$121$35,93338 claims
MerckJanuvia$24$30,67321 claims
Astellas Pharma US IncMyrbetriq$84$21,53419 claims
Boehringer IngelheimJardiance$460$18,51113 claims
AbbVieLinzess, Synthroid$143$18,36472 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →